Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

BioXcel files for bankruptcy, will sell assets to Teva for up to $125M

29 August 2026 · By · Wire by Fusion42

Published

29 August 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at biospace.com →

◆ Verified

Fusion42 · 29 August 2026 · Fusion42 review

BioXcel Therapeutics filed for Chapter 11 bankruptcy and plans to sell its AI-derived neuroscience drug assets to Teva Pharmaceuticals for up to $125 million, with Teva acting as the stalking horse bidder to initiate the auction process.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Teva’s role as stalking horse bidder with milestone payments signals a strategic opening to acquire AI-driven drug assets, marking a window for biotech founders to watch for displaced opportunities in AI neuroscience therapeutics.

◆ Coverage

1 source · 29 Aug 2026

◆ Related on Wire

◆ Topics

Biotechbankruptcyasset-salepharmaceuticalsAI-drugsTeva